CN104903343A - 抗乙型肝炎病毒的疫苗 - Google Patents

抗乙型肝炎病毒的疫苗 Download PDF

Info

Publication number
CN104903343A
CN104903343A CN201380067602.2A CN201380067602A CN104903343A CN 104903343 A CN104903343 A CN 104903343A CN 201380067602 A CN201380067602 A CN 201380067602A CN 104903343 A CN104903343 A CN 104903343A
Authority
CN
China
Prior art keywords
peptide
seq
hbv
peptides
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380067602.2A
Other languages
English (en)
Chinese (zh)
Inventor
伯特兰·维克托·吉尔伯特·乔治斯
卡尔顿·布兰得利·布朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altimmune UK Ltd
Original Assignee
Altimmune UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altimmune UK Ltd filed Critical Altimmune UK Ltd
Priority to CN202111025902.7A priority Critical patent/CN114028553A/zh
Publication of CN104903343A publication Critical patent/CN104903343A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201380067602.2A 2012-12-24 2013-12-20 抗乙型肝炎病毒的疫苗 Pending CN104903343A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111025902.7A CN114028553A (zh) 2012-12-24 2013-12-20 包括免疫原性肽组合的药物组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1223386.2A GB201223386D0 (en) 2012-12-24 2012-12-24 Vaccine
GB1223386.2 2012-12-24
PCT/GB2013/053410 WO2014102540A1 (en) 2012-12-24 2013-12-20 Vaccines against hepatitis b virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111025902.7A Division CN114028553A (zh) 2012-12-24 2013-12-20 包括免疫原性肽组合的药物组合物

Publications (1)

Publication Number Publication Date
CN104903343A true CN104903343A (zh) 2015-09-09

Family

ID=47682590

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380067602.2A Pending CN104903343A (zh) 2012-12-24 2013-12-20 抗乙型肝炎病毒的疫苗
CN202111025902.7A Pending CN114028553A (zh) 2012-12-24 2013-12-20 包括免疫原性肽组合的药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111025902.7A Pending CN114028553A (zh) 2012-12-24 2013-12-20 包括免疫原性肽组合的药物组合物

Country Status (12)

Country Link
US (3) US10300132B2 (enExample)
EP (2) EP2935313B1 (enExample)
JP (3) JP6811014B2 (enExample)
KR (3) KR102625645B1 (enExample)
CN (2) CN104903343A (enExample)
CA (1) CA2895459A1 (enExample)
DK (1) DK2935313T3 (enExample)
EA (1) EA201591213A1 (enExample)
ES (1) ES2906110T3 (enExample)
GB (1) GB201223386D0 (enExample)
PL (1) PL2935313T3 (enExample)
WO (1) WO2014102540A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017071467A1 (zh) * 2015-10-26 2017-05-04 复旦大学 评价疫苗疗效的细胞免疫学检测试剂盒及其储存方法
CN112638410A (zh) * 2018-04-04 2021-04-09 艾尔特免疫公司 诱导t细胞的疫苗组合物组合及其用途
CN115335076A (zh) * 2020-01-09 2022-11-11 病毒治疗有限责任公司 编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
WO2016020538A1 (en) * 2014-08-08 2016-02-11 Transgene Sa Hbv vaccine and antibody combination therapy to treat hbv infections
US11419927B2 (en) 2016-06-02 2022-08-23 Ultimovacs As Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
AU2017281389B2 (en) 2016-06-20 2024-02-22 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine
CA3085492A1 (en) * 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines
WO2020145901A1 (en) * 2019-01-11 2020-07-16 Agency For Science, Technology And Research Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells
WO2020255018A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Hepatitis b virus (hbv) vaccines and uses thereof
PH12022550490A1 (en) * 2019-08-29 2023-02-06 Triad Nat Security Llc Hepatitis b virus vaccines
JP2023505304A (ja) * 2019-12-07 2023-02-08 アイエスエー ファーマシューティカルズ ビー．ヴイ． Ｂ型肝炎ウイルスに関連する疾患の治療
EP4161644A2 (en) * 2020-06-08 2023-04-12 F. Hoffmann-La Roche AG Anti-hbv antibodies and methods of use
WO2023085956A1 (en) * 2021-11-09 2023-05-19 Avalia Immunotherapies Limited Novel therapeutic vaccines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003753A1 (en) * 1991-08-26 1993-03-04 The Scripps Research Institute Peptides for inducing cytotoxic t-lymphocyte responses to hepatitis b virus
WO1995003777A1 (en) * 1993-08-02 1995-02-09 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607727B1 (en) * 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
CN1454082A (zh) 2000-09-08 2003-11-05 艾普免疫公司 使用肽和核酸组合物诱导针对乙型肝炎病毒的细胞免疫应答
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
US10076570B2 (en) * 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
GB201022147D0 (en) 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003753A1 (en) * 1991-08-26 1993-03-04 The Scripps Research Institute Peptides for inducing cytotoxic t-lymphocyte responses to hepatitis b virus
WO1995003777A1 (en) * 1993-08-02 1995-02-09 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEN.Z.等: "Accession NO.:AFZ88277.1，", 《GENBANK DATABASE》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017071467A1 (zh) * 2015-10-26 2017-05-04 复旦大学 评价疫苗疗效的细胞免疫学检测试剂盒及其储存方法
CN112638410A (zh) * 2018-04-04 2021-04-09 艾尔特免疫公司 诱导t细胞的疫苗组合物组合及其用途
CN115335076A (zh) * 2020-01-09 2022-11-11 病毒治疗有限责任公司 编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法

Also Published As

Publication number Publication date
KR102625645B1 (ko) 2024-01-15
JP7187237B2 (ja) 2022-12-12
JP6811014B2 (ja) 2021-01-13
EP2935313B1 (en) 2021-11-24
JP2019034946A (ja) 2019-03-07
KR20150098676A (ko) 2015-08-28
US20200016263A1 (en) 2020-01-16
KR102358621B1 (ko) 2022-02-03
KR20220019846A (ko) 2022-02-17
KR20230021771A (ko) 2023-02-14
JP2021098711A (ja) 2021-07-01
KR102497063B1 (ko) 2023-02-06
US10300132B2 (en) 2019-05-28
CN114028553A (zh) 2022-02-11
CA2895459A1 (en) 2014-07-03
WO2014102540A1 (en) 2014-07-03
US20230090379A1 (en) 2023-03-23
DK2935313T3 (da) 2022-02-28
JP7235785B2 (ja) 2023-03-08
US20160106830A1 (en) 2016-04-21
EP3995146A1 (en) 2022-05-11
EP2935313A1 (en) 2015-10-28
JP2016505589A (ja) 2016-02-25
US11918645B2 (en) 2024-03-05
US11382969B2 (en) 2022-07-12
GB201223386D0 (en) 2013-02-06
EA201591213A1 (ru) 2016-02-29
PL2935313T3 (pl) 2022-05-02
ES2906110T3 (es) 2022-04-13

Similar Documents

Publication Publication Date Title
US11918645B2 (en) Vaccines against hepatitis B virus
JP3738395B2 (ja) Ｈｌａ−制限型ｂ型肝炎ウィルスのｃｔｌエピトープ
JP3650110B2 (ja) Ｂ型肝炎ウイルスに対する細胞毒性ｔリンパ球応答を誘発するためのペプチド
AU2001282706B2 (en) HIV peptides from conserved in gag p17 and 924 and their application in E.G. vaccines
US20160199469A1 (en) Oncology vaccine
JP3616390B2 (ja) Ｂ型肝炎のウイルスに対する細胞障害性ｔリンパ球の応答を誘発するペプチド
Shi et al. Therapeutic polypeptides based on HBcAg18-27 CTL epitope can induce antigen-specific CD8+ CTL-mediated cytotoxicity in HLA-A2 transgenic mice
JP2010029217A (ja) Ｈｉｖ特異的ｃｔｌを誘導し得るペプチド及び該ペプチドを含む抗ａｉｄｓ予防・治療剤
HK40067424A (en) Pharmaceutical compositions comprising combination of immunogenic peptides
CN1625409B (zh) 含可变肽表位的免疫原制剂及其制备方法
WO2004092207A2 (en) Respiratory syncytial virus (rsv) peptides
AU1906592A (en) Peptides for use in induction of t cell activation against hiv-1
BR112015015198B1 (pt) Composição farmacêutica, e, vetor de fluorcarbono
AU727738B2 (en) Compositions and methods for eliciting CTL immunity

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: London, England

Applicant after: Otimny UK Limited

Address before: London, England

Applicant before: IMMUNE TARGETING SYSTEMS ITS LTD

CB02 Change of applicant information
RJ01 Rejection of invention patent application after publication

Application publication date: 20150909

RJ01 Rejection of invention patent application after publication